These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35467794)
1. Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up. Suresh S; Charlton D; Snell EK; Laffoon M; Medsger TA; Zhu L; Domsic RT Arthritis Rheumatol; 2022 Sep; 74(9):1580-1587. PubMed ID: 35467794 [TBL] [Abstract][Full Text] [Related]
2. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis. Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424 [TBL] [Abstract][Full Text] [Related]
3. Anti-Th/To antibodies in systemic sclerosis: analysis of long-term follow-up of pulmonary involvement, organ damage accrual and mortality in an Italian cohort with a case-control study. Moschetti L; Lazzaroni MG; Cavazzana I; Franceschini F; Airò P Clin Exp Rheumatol; 2023 Aug; 41(8):1589-1598. PubMed ID: 36762745 [TBL] [Abstract][Full Text] [Related]
4. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515 [TBL] [Abstract][Full Text] [Related]
5. Determinants of morbidity and mortality of systemic sclerosis in Canada. Al-Dhaher FF; Pope JE; Ouimet JM Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680 [TBL] [Abstract][Full Text] [Related]
6. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517 [TBL] [Abstract][Full Text] [Related]
7. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572 [TBL] [Abstract][Full Text] [Related]